Will we ever know for sure how COVID-19 began? Not without more data from China, WHO says
Scientists still aren't sure how the COVID-19 pandemic – the worst health emergency in a century – began.
That was the unsatisfying conclusion from an expert group charged by the World Health Organization (WHO) to investigate the pandemic's origins in its final report.
Marietjie Venter, the group's chair, said at a press briefing that most scientific data supports the hypothesis that the new coronavirus jumped to humans from animals.
That was also the conclusion drawn by the first WHO expert group that investigated the pandemic's origins in 2021, when scientists concluded the virus likely spread from bats to humans, via another intermediary animal.
At the time, WHO said a lab leak was 'extremely unlikely'.
Related
Five years after COVID appeared, mysteries remain. Here's what we know
Venter said that after more than three years of work, WHO's expert group was unable to get the necessary data to evaluate whether or not COVID-19 was the result of a lab accident, despite repeated requests for hundreds of genetic sequences and more detailed biosecurity information that were made to the Chinese government.
'Therefore, this hypothesis could not be investigated or excluded,' she said. 'It was deemed to be very speculative, based on political opinions and not backed up by science'.
She said that the 27-member group did not reach a consensus; one member resigned earlier this week and three others asked for their names to be removed from the report.
Venter said there was no evidence to prove that COVID-19 had been manipulated in a lab, nor was there any indication that the virus had been spreading before December 2019 anywhere outside of China.
Related
Italy honours COVID-19 victims on remembrance day, five years after pandemic hit
'Until more scientific data becomes available, the origins of how SARS-CoV-2 entered human populations will remain inconclusive,' Venter said, referring to the scientific name for the COVID-19 virus.
WHO Director-General Tedros Adhanom Ghebreyesus said it was a 'moral imperative' to determine how COVID began, noting that the virus killed at least 20 million people, wiped at least $10 trillion (€8.8 trillion) from the global economy and upended the lives of billions of people.
Last year, the AP found that the Chinese government froze meaningful domestic and international efforts to trace the virus' origins in the first weeks of the outbreak in 2020 and that WHO itself may have missed early opportunities to investigate how COVID-19 began.
Related
New CIA assessment claims COVID-19 virus 'probably' came from Chinese laboratory
US President Donald Trump has long blamed the emergence of the coronavirus on a laboratory accident in China, while a US intelligence analysis found there was insufficient evidence to prove the theory.
Chinese officials have repeatedly dismissed the idea that the pandemic could have started in a lab, saying that the search for its origins should be conducted in other countries.
Last September, researchers zeroed in on a short list of animals they think might have spread COVID-19 to humans, including racoon dogs, civet cats, and bamboo rats.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
How does Alberta's new COVID-19 vaccine policy compare to other provinces? We asked
Alberta's decision to reduce access to publicly funded COVID-19 vaccines so far appears to set the province on a different course than many other Canadian jurisdictions. Most Albertans will no longer be eligible for a free COVID-19 shot this fall. The provincial government recently announced plans to limit coverage to specific high risk groups, including Albertans living in care homes and group settings, those receiving home care, people on social programs such as AISH, and immunocompromised individuals. All other seniors, pregnant Albertans and health care workers are not included, despite strong recommendations by the National Advisory Committee on Immunization (NACI) that they should be vaccinated. NACI also recommends that everyone else may receive an annual dose. The Alberta government has cited vaccine waste as a key reason for its decision. It pegs the cost at roughly $110 per dose and estimates $135 million worth of vaccines have been discarded. "I think over the last number of years we've seen Alberta become more of an outlier when it comes to vaccine policy and vaccine programming," said Dr. Samir Sinha, a geriatrician and director of health policy research at the National Institute on Ageing. "As far as I know right now Alberta is the only province in the country that has diverged from the NACI recommendations." The change has come about as responsibility for ordering and buying COVID-19 shots shifts from the federal government to the provinces and territories. CBC News reached out to each province and territory to find out how they're handling COVID-19 vaccine coverage moving forward. Most responded prior to publication time. British Columbia said it will continue to provide universal coverage. That means all B.C. residents six months of age and older will be eligible for free COVID-19 vaccines this fall and winter. The province's Ministry of Health said those who are at high risk will be strongly encouraged to get a dose. Ontario pointed to its policy, which states that all residents six months of age and up are eligible for COVID-19 vaccination each fall. The website states annual shots are free of charge. The Saskatchewan government is still developing its fall and winter immunization policy but told CBC News it is "committed to providing a COVID-19 immunization program based on scientific evidence and clinical expert recommendations made by the National Advisory Committee on Immunization (NACI)." Manitoba has signalled it will ensure COVID-19 vaccines are available and free to the public. When asked whether Manitoba would follow Alberta's lead at a recent press conference, Manitoba Health Minister Uzoma Asagwara was unequivocal. "Vaccines are important. We are a government that believes in science," Asagwara said. "COVID vaccines will be readily available for Manitobans at the right time. There will be no charge. There are lots of vaccines that we're encouraging people to get. We listen to our public health experts." Nunavut's government said it also intends to follow NACI guidance. A spokesperson said the territory will continue offering COVID shots for free to all residents with priority given to high risk groups including elders aged 65 and up, people with chronic medical conditions, those in long-term care, pregnant individuals and others. A spokesperson for the government of Northwest Territories told CBC News it is working to align its policy with NACI guidance and that the vaccine remains free of charge to all individuals who believe they are high risk, including seniors and people who are moderately to severely immunocompromised. Nova Scotia said it too will continue to provide free COVID-19 shots, based on the NACI guidance. And Quebec and New Brunswick told CBC News they're still finalizing their plans for this fall. Fiona Clement, a professor in the department of community health sciences at the University of Calgary's Cumming School of Medicine, said Alberta is "really going in a different direction than the other provinces are moving in." She pointed out that Alberta continues to offer many other vaccines — ranging from childhood immunizations to annual flu shots — for free. "I do think it underscores that COVID is politicized in a way that other diseases have not been. And it's a bit disappointing to see when really COVID is a very serious infectious disease," Clement said. Provincial data shows 373 Albertans died due to COVID-19 from August 2024 to June 21, 2025. Influenza resulted in 235 deaths during the same time period. In addition to reducing access, the Alberta government is no longer allowing pharmacies to offer COVID vaccines. They will have to be booked through public health clinics. Albertans are expected to pre-order their doses starting on Aug. 11. "There's a wealth of evidence that demonstrates the more barriers you put up, the lower uptake is," Clement said. "I think we can expect lower vaccination rates, higher hospitalization rates and higher death rates. And that's really disappointing." The Alberta government, meanwhile, called the move a "responsible, targeted approach." "Following the federal government's recent decision to no longer provide COVID-19 vaccines free of charge, Alberta is introducing a cost-recovery model to help offset procurement costs and ensure a sustainable solution for Albertans," an emailed statement from the office of the minister of Primary and Preventative Health Services said, in part. "Alberta's decisions on coverage and access, while informed by NACI's broad recommendations, are tailored to the province's specific needs, taking into account factors … including expected uptake, previous wastage, and the number of individuals most vulnerable to severe outcomes." The provincial government also points to declining COVID-19 vaccination rates. Alberta's respiratory virus dashboard shows 13.7 per cent of Albertans received a COVID-19 shot during the last respiratory virus season. "And vaccine uptake among lower-risk groups has declined significantly in recent seasons," the statement said. "Reflecting these realities, Alberta's COVID-19 vaccine program will focus on high-risk populations most vulnerable to severe outcomes, while ensuring the best use of taxpayer dollars." Meanwhile, Sinha, the director of health policy research at the National Institute on Ageing, questioned whether Alberta's decision could spark other provinces to back off their coverage plans down the line. "Now that Alberta is saying that we're no longer going to cover it for everybody — that NACI would recommend otherwise to be covered — this might open the other door for other provinces that were hedging as well to say, 'If Alberta's not going to cover everyone, neither should we,'" he said. While the provincial government said its policy followed national guidance, Sinha echoed concerns from other doctors who argue the province is deviating from NACI's recommendations. He's worried all this will create confusion moving forward. "My concern about what Alberta's approach is right now is that it's creating less confidence, less convenience and more cost and more barriers to getting vaccinated, which I think is ultimately going to worsen the public health of Albertans," he said.
Yahoo
an hour ago
- Yahoo
Chungnam National University and SCIEX Accelerate the Realization of "Industry on Campus" with Global Headquarters Alliance
Strategic MOU signed with global mass spectrometry leader SCIEX SEOUL, South Korea, June 30, 2025--(BUSINESS WIRE)--SCIEX, a global leader in life science analytical technologies, signed a strategic Memorandum of Understanding (MOU) with Chungnam National University. The agreement, signed by Chris Hagen, President of SCIEX, and Kim Jung-Kyum, President of Chungnam National University, emphasizes the significance of this strategic alliance between the two institutions. This MOU represents a pivotal first step in realizing Chungnam National University's "Industry on Campus" vision, which aims to break down the barriers between academia and industry, and foster an innovative ecosystem that integrates education, research, and enterprise. Chungnam National University plans to actively incorporate cutting-edge mass spectrometry technologies from SCIEX into its education and research programs. This could enhance the university's global competitiveness in precision analysis across key fields such as biotechnology, pharmaceuticals, omics, environment, and food sciences. SCIEX has led the global life sciences and analytical sciences sectors for over 50 years with high-precision analytical solutions. This collaboration with Chungnam National University is anticipated to: Provide advanced mass spectrometry equipment and technical infrastructure Launch joint research project initiatives Organize seminars and technical workshops Boost cooperation on educational programs Through this agreement, the two institutions aim to work together to build a collaborative research ecosystem and a global industry-academia cooperation model. This could establish a virtuous cycle that promotes the dissemination of advanced analytical technologies, provides hands-on educational environments, and nurtures next-generation research talent. The signing ceremony was attended by Jeong Kyoum Kim (President, Chungnam National University), Hyun Joo An (Vice President for International Affairs, Chungnam National University), Chris Hagen (President of SCIEX), and Lawrence Chia (Vice President and GM of SCIEX J-KOSEA), who each share the vision to build a joint research ecosystem based on global-level technological cooperation. President Kim stated, "This agreement will serve as a practical implementation of Chungnam National University's Industry on Campus strategy. Through our alliance with SCIEX, we will expand joint research based on advanced analytical technologies and establish an innovation platform that connects education, research, and industry." SCIEX President Chris Hagen added, "We hope this collaboration with Chungnam National University marks the beginning of a true strategic alliance to empower the bright minds who will lead the future of science and technology. SCIEX will continue to contribute to the advancement of Korea's research ecosystem with our global analytical technologies." This MOU is expected to contribute to innovation and industrial advancement in the field of analytical science through a sustainable collaboration between a leading national university and a global analytical instrumentation company. About SCIEX SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Advances in human wellness depend on the power of precise science. For more information, visit Connect with us on LinkedIn, Facebook, and Instagram. The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see © 2025 DH Tech. Dev. Pte. Ltd. MKT- 35606-A. View source version on Contacts Lulu VanZandtSenior manager, brand, public relations and social M: +1 (508) 782-9484 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone SHANGHAI & CAMBRIDGE, Mass., June 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need. In China, there are over 350,000 new cases each year. The disease is associated with a poor prognosis, particularly in advanced stages where the five-year survival rate is less than 10%. There are currently no approved therapies specifically targeting FGFR2b overexpression in gastric cancer in China. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting. Zai Lab holds the development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan. Bemarituzumab has been granted Breakthrough Therapy designation by the China Center for Drug Evaluation of the National Medical Products Administration for the treatment of FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025. About FGFR2b The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2 The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3 About FORTITUDE-101 FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled. The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining. Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab. About Gastric Cancer in China Gastric cancer is the fifth most common cancer worldwide, while China bears one of the highest gastric cancer burdens in the world with an estimated 358,700 new cases and 260,400 deaths annually.4 In China, approximately 80% of gastric cancer patients are diagnosed at an advanced or metastatic stage5. For those diagnosed with Stage IV gastric cancer, the overall 5-year survival rate is less than 10%6. Patients with advanced gastric and GEJ cancer that overexpress the FGFR2b protein may be associated with poor prognosis7-10. About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding the prospects and plans for developing and commercializing bemarituzumab, the potential benefits of bemarituzumab, and the potential treatment of gastric and gastroesophageal junction cancer. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at REFERENCES Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263 Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40 Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. Health Commission of The People's Republic Of China N. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):207-237. Li HQ, Zhang H, Zhang HJ, Wang YX, Wang XB, Hou HF. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. J Glob Health 2022;12:11014. Catenacci D, et al. Presented at American Society of Clinical Oncology; June 4-8, 2021; Online Virtual Scientific Program. Abstract 4010. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. Ishiwata T. Front Biosci (Landmark Ed). 2018;23:626-639. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data